- Home
- KXIN vs REVB Comparison
KXIN vs REVB Comparison
Compare KXIN & REVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KXIN
- REVB
- Stock Information
- Founded
- KXIN 2015
- REVB 2020
- Country
- KXIN China
- REVB United States
- Employees
- KXIN N/A
- REVB N/A
- Industry
- KXIN Retail-Auto Dealers and Gas Stations
- REVB Biotechnology: Pharmaceutical Preparations
- Sector
- KXIN Consumer Discretionary
- REVB Health Care
- Exchange
- KXIN Nasdaq
- REVB Nasdaq
- Market Cap
- KXIN 3.0M
- REVB 3.1M
- IPO Year
- KXIN N/A
- REVB N/A
- Fundamental
- Price
- KXIN $2.60
- REVB $0.80
- Analyst Decision
- KXIN
- REVB
- Analyst Count
- KXIN 0
- REVB 0
- Target Price
- KXIN N/A
- REVB N/A
- AVG Volume (30 Days)
- KXIN 3.0M
- REVB 1.3M
- Earning Date
- KXIN 01-01-0001
- REVB 11-08-2024
- Dividend Yield
- KXIN N/A
- REVB N/A
- EPS Growth
- KXIN N/A
- REVB N/A
- EPS
- KXIN N/A
- REVB N/A
- Revenue
- KXIN $12,679,000.00
- REVB N/A
- Revenue This Year
- KXIN N/A
- REVB N/A
- Revenue Next Year
- KXIN N/A
- REVB N/A
- P/E Ratio
- KXIN N/A
- REVB N/A
- Revenue Growth
- KXIN N/A
- REVB N/A
- 52 Week Low
- KXIN $2.28
- REVB $0.70
- 52 Week High
- KXIN $148.86
- REVB $25.26
- Technical
- Relative Strength Index (RSI)
- KXIN 38.07
- REVB 44.03
- Support Level
- KXIN $2.80
- REVB $0.80
- Resistance Level
- KXIN $7.30
- REVB $1.05
- Average True Range (ATR)
- KXIN 0.86
- REVB 0.07
- MACD
- KXIN -0.09
- REVB -0.00
- Stochastic Oscillator
- KXIN 6.37
- REVB 9.69
About KXIN Kaixin Auto Holdings
Kaixin Holdings is an auto retail platform for luxury used cars and imported new cars. The company is actively engaged in the research and development, design, manufacturing, and sales of electric vehicles and promotes the innovation of next-generation autonomous driving and artificial intelligence technologies. The company primarily generates revenues from sales of used cars, as well as fees obtained from its role as a channel partner for third-party auto financing and other value-added service providers.
About REVB Revelation Biosciences Inc.
Revelation Biosciences Inc is a clinical-stage life sciences company focused on the development of therapies for the prevention and treatment of disease using trained immunity. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).